newsfilter
← Latest News
GlobeNewswire·

Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

  • Artiva Biotherapeutics management will participate in a fireside chat at the Stifel 2026 Virtual Immunology & Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT.
  • The company is initiating a Phase 3 registrational trial for its lead program, AlloNK (AB-101), in refractory rheumatoid arthritis during the second half of 2026.
  • AlloNK is an allogeneic, off-the-shelf, non-genetically modified NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity & drive deep B-cell depletion.
  • Initial clinical data for AlloNK combined with anti-CD20 antibodies show encouraging activity across multiple B-cell-driven autoimmune diseases with a tolerability profile suitable for outpatient administration.
  • The company is also evaluating AlloNK for Sjögren disease, systemic sclerosis, & myositis.
  • An archived audio webcast of the forum presentation will be available on Artiva's website for 90 days.